Кеуде безінің рентгенмен тексеруі (маммография)

Process of using low energy X rays to examine the human breast for diagnosis and screening

Mammography (also called mastography: DICOM modality = MG) is the process of using low energy X rays (usually around 30 kVp) to examine the human breast for diagnosis and screening. The goal of mammography is the early detection of breast cancer, typically through detection of characteristic masses or microcalcifications. As with all X rays, mammograms use doses of ionizing radiation to create images. These images are then analyzed for abnormal findings. It is usual to employ lower energy X rays, typically Mo (K shell X ray energies of 17.5 and 19.6 keV) and Rh (20.2 and 22.7 keV) than those used for radiography of bones. Mammography may be 2D or 3D (tomosynthesis), depending on the available equipment and/or purpose of the examination. Ultrasound, ductography, positron emission mammography (PEM), and magnetic resonance imaging (MRI) are adjuncts to mammography. Ultrasound is typically used for further evaluation of masses found on mammography or palpable masses that may or may not be seen on mammograms. Ductograms are still used in some institutions for evaluation of bloody nipple discharge when the mammogram is non diagnostic. MRI can be useful for the screening of high risk patients, for further evaluation of questionable findings or symptoms, as well as for pre surgical evaluation of patients with known breast cancer, in order to detect additional lesions that might change the surgical approach (for example, from breast conserving lumpectomy to mastectomy). In 2023, the U. S. Preventive Services Task Force issued a draft recommendation statement that all women should receive a screening mammography every two years from age 40 to 74. The American College of Radiology and American Cancer Society recommend yearly screening mammography starting at age 40. The Canadian Task Force on Preventive Health Care (2012) and the European Cancer Observatory (2011) recommend mammography every 2 to 3 years between ages 50 and 69. These task force reports point out that in addition to unnecessary surgery and anxiety, the risks of more frequent mammograms include a small but significant increase in breast cancer induced by radiation. Additionally, mammograms should not be performed with increased frequency in patients undergoing breast surgery, including breast enlargement, mastopexy, and breast reduction.

Digital mammography is a specialized form of mammography that uses digital receptors and computers instead of X ray film to help examine breast tissue for breast cancer. The electrical signals can be read on computer screens, permitting more manipulation of images to allow radiologists to view the results more clearly Digital mammography may be "spot view", for breast biopsy, or "full field" (FFDM) for screening. had hoped for more marked improvement, the effectiveness of digital mammography was found comparable to traditional X ray methods in 2004, though there may be reduced radiation with the technique and it may lead to fewer retests. The U. S. Preventive Services Task Force concluded that there was insufficient evidence to recommend for or against digital mammography. Digital mammography is a NASA spin off, utilizing technology developed for the Hubble Space Telescope. As of 2007, about 8% of American screening centers used digital mammography. Around the globe, systems by Fujifilm Corporation are the most widely used. In the United States, GE's digital imaging units typically cost US$300,000 to $500,000, far more than film based imaging systems. Cost effectiveness is unclear as of 2016. Another concern is that it more than doubles the radiation exposure.

Photon counting mammography was introduced commercially in 2003 and was shown to reduce the X ray dose to the patient by approximately 40% compared to conventional methods while maintaining image quality at an equal or higher level. The technology was subsequently developed to enable spectral imaging with the possibility to further improve image quality, to distinguish between different tissue types, and to measure breast density.

A galactography (or breast ductography) is a now infrequently used type of mammography used to visualize the milk ducts. Prior to the mammography itself, a radiopaque substance is injected into the duct system. This test is indicated when nipple discharge exists.

Mammography can detect cancer early when it’s most treatable and can be treated less invasively (thereby helping to preserve quality of life). According to National Cancer Institute data, since mammography screening became widespread in the mid 1980s, the U. S. breast cancer death rate, unchanged for the previous 50 years, has dropped well over 30 percent. In European countries like Denmark and Sweden, where mammography screening programs are more organized, the breast cancer death rate has been cut almost in half over the last 20 years. Mammography screening cuts the risk of dying from breast cancer nearly in half. A recent study published in Cancer showed that more than 70 percent of the women who died from breast cancer in their 40s at major Harvard teaching hospitals were among the 20 percent of women who were not being screened. Some scientific studies have shown that the most lives are saved by screening beginning at age 40. A recent study in the British Medical Journal shows that early detection of breast cancer – as with mammography – significantly improves breast cancer survival. The benefits of mammography screening at decreasing breast cancer mortality in randomized trials are not found in observational studies performed long after implementation of breast cancer screening programs (for instance, Bleyer et al.)

In 2014, the Surveillance, Epidemiology, and End Results Program of the National Institutes of Health reported the occurrence rates of breast cancer based on 1000 women in different age groups. In the 40–44 age group, the incidence was 1.5 and in the 45–49 age group, the incidence was 2.3. The National Cancer Institute encourages mammograms every one to two years for women ages 40 to 49. In 2023, United States Preventive Services Task Force (USPSTF) revised the recommendation that women and transgender men undergo biennial mammograms starting at the age of 40, rather than the previously suggested age of 50. This adjustment is prompted by the increasing incidence of breast cancer in the 40 to 49 age group over the past decade. In contrast, the American College of Physicians, a large internal medicine group, has recently encouraged individualized screening plans as opposed to wholesale biannual screening of women aged 40 to 49. The American Cancer Society recommendations for women at average risk for breast cancer is a yearly mammogram from age 45 to 54 with an optional yearly mammogram from age 40 to 44.

The radiation exposure associated with mammography is a potential risk of screening, which appears to be greater in younger women. In scans where women receive 0.25–20 Gray (Gy) of radiation, they have more of an elevated risk of developing breast cancer. A study of radiation risk from mammography concluded that for women 40 years of age and older, the risk of radiation induced breast cancer was minuscule, particularly compared with the potential benefit of mammographic screening, with a benefit to risk ratio of 48.5 lives saved for each life lost due to radiation exposure. This also correlates to a decrease in breast cancer mortality rates by 24%. Experiencing pain is a significant predictor in women not re attending screening. There are few proven interventions to reduce pain in mammography, but evidence suggests that giving women information about the mammography procedure prior to it taking place may reduce the pain and discomfort experienced. Furthermore, research has found that standardised compression levels can help to reduce patients' pain while still allowing for optimal diagnostic images to be produced.

Mammogram results are often expressed in terms of the BI RADS Assessment Category, often called a "BI RADS score". This was developed by the American College of Radiology in 1993 in order to provide referring clinicians and patients a clear, meaningful and standardized report. The findings of a mammogram are divided into five main categories: mass, asymmetry, architectural distortion, calcifications, and associated features. Each has additional subcategories to further describe findings. After providing a description of the findings, the radiologist provides a final assessment ranging from 0 to 6. BI RADS 0 indicates an incomplete assessment which needs additional imaging. BI RADS 1 & 2 indicate a negative and benign screen mammogram respectively. BI RADS 3 indicates probably benign. BI RADS 4 indicates suspicious for malginancy. BI RADS 5 indicates highly suggestive of malignancy. BI RADS 6 is for biopsy proven breast cancer. A BI RADS 3, 4, 5, and 6 would require further investigation with a diagnostic mammogram. In the UK mammograms are scored on a scale from 1–5 (1 = normal, 2 = benign, 3 = indeterminate, 4 = suspicious of malignancy, 5 = malignant). Evidence suggests that accounting for genetic risk, factors improve breast cancer risk prediction.

In the past several years, the "work up" process has become highly formalized. It generally consists of screening mammography, diagnostic mammography, and biopsy when necessary, often performed via stereotactic core biopsy or ultrasound guided core biopsy. After a screening mammogram, some women may have areas of concern which cannot be resolved with only the information available from the screening mammogram. They would then be called back for a "diagnostic mammogram". This phrase essentially means a problem solving mammogram. During this session, the radiologist will be monitoring each of the additional films as they are taken by a radiographer. Depending on the nature of the finding, ultrasound may often be used as well. Generally, the cause of the unusual appearance is found to be benign. If the cause cannot be determined to be benign with sufficient certainty, a biopsy may be recommended. The biopsy procedure will be used to obtain actual tissue from the site for the pathologist to examine microscopically to determine the precise cause of the abnormality. In the past, biopsies were most frequently done in surgery, under local or general anesthesia. The majority are now done with needles in conjunction with either ultrasound or mammographic guidance to be sure that the area of concern is the area that is biopsied. These core biopsies require only local anesthesia, similar to what would be given during a minor dental procedure.

As a medical procedure that induces ionizing radiation, the origin of mammography can be traced to the discovery of X rays by Wilhelm Röntgen in 1895. In 1913, German surgeon Albert Salomon performed a mammography study on 3,000 mastectomies, comparing X rays of the breasts to the actual removed tissue, observing specifically microcalcifications. By doing so, he was able to establish the difference as seen on an X ray image between cancerous and non cancerous tumors in the breast. In 1930, American physician and radiologist Stafford L. Warren published "A Roentgenologic Study of the Breast", a study where he produced stereoscopic X rays images to track changes in breast tissue as a result of pregnancy and mastitis. In 119 women who subsequently underwent surgery, he correctly found breast cancer in 54 out of 58 cases. In 1949, Raul Leborgne sparked renewed enthusiasm for mammography by emphasizing the importance of technical proficiency in patient positioning and the adoption of specific radiological parameters. He played a pioneering role in elevating imaging quality while placing particular emphasis on distinguishing between benign and malignant calcifications. In the early 1950s, Uruguayan radiologist Raul Leborgne developed the breast compression technique to produce better quality images, and described the differences between benign and malign microcalcifications. In 1956, Gershon Cohen conducted clinical trails on over 1,000 asymptomatic women at the Albert Einstein Medical Center on his screening technique, The "Egan technique", as it became known, enabled physicians to detect calcification in breast tissue; of the 245 breast cancers that were confirmed by biopsy among 1,000 patients, Egan and his colleagues at M. D. Anderson were able to identify 238 cases by using his method, 19 of which were in patients whose physical examinations had revealed no breast pathology. Use of mammography as a screening technique spread clinically after a 1966 study demonstrating the impact of mammograms on mortality and treatment led by Philip Strax. This study, based in New York, was the first large scale randomized controlled trial of mammography screening. In 1985, László Tabár and colleagues documented findings from mammographic screening involving 134,867 women aged 40 to 79. Using a single mediolateral oblique image, they reported a 31% reduction in mortality. Keen and Keen indicated that repeated mammography starting at age fifty saves about 1.8 lives over 15 years for every 1,000 women screened. This result has to be seen against the adverse effects of errors in diagnosis, over treatment, and radiation exposure. The Cochrane analysis of screening indicates that it is "not clear whether screening does more good than harm". According to their analysis, 1 in 2,000 women will have her life prolonged by 10 years of screening, while 10 healthy women will undergo unnecessary breast cancer treatment. Additionally, 200 women will experience significant psychological stress due to false positive results. The Cochrane Collaboration (2013) concluded after ten years that trials with adequate randomization did not find an effect of mammography screening on total cancer mortality, including breast cancer. The authors of this Cochrane review write: "If we assume that screening reduces breast cancer mortality by 15% and that overdiagnosis and over treatment is at 30%, it means that for every 2,000 women invited for screening throughout 10 years, one will avoid dying of breast cancer and 10 healthy women, who would not have been diagnosed if there had not been screening, will be treated unnecessarily. Furthermore, more than 200 women will experience important psychological distress including anxiety and uncertainty for years because of false positive findings." The authors conclude that the time has come to re assess whether universal mammography screening should be recommended for any age group. The Nordic Cochrane Collection updated research in 2012 and stated that advances in diagnosis and treatment make mammography screening less effective today, rendering it "no longer effective". They conclude that "it therefore no longer seems reasonable to attend" for breast cancer screening at any age, and warn of misleading information on the internet. The Nordic Cochrane Collection notes that advances in diagnosis and treatment of breast cancer may make breast cancer screening no longer effective in decreasing death from breast cancer, and therefore no longer recommend routine screening for healthy women as the risks might outweigh the benefits. About 10% of those who are called back will be referred for a biopsy. Of the 10% referred for biopsy, about 3.5% will have cancer and 6.5% will not. Of the 3.5% who have cancer, about 2 will have an early stage cancer that will be cured after treatment. Mammography may also produce false negatives. Estimates of the numbers of cancers missed by mammography are usually around 20%. Reasons for not seeing the cancer include observer error, but more frequently it is because the cancer is hidden by other dense tissue in the breast, and even after retrospective review of the mammogram the cancer cannot be seen. Furthermore, one form of breast cancer, lobular cancer, has a growth pattern that produces shadows on the mammogram that are indistinguishable from normal breast tissue.

The Cochrane Collaboration states that the best quality evidence does not demonstrate a reduction in mortality or a reduction in mortality from all types of cancer from screening mammography. In practice, the vast majority of these women received no practical benefit from the mammogram. There are four categories of cancers found by mammography:
Cancers that are so easily treated that a later detection would have produced the same rate of cure (women would have lived even without mammography). Cancers so aggressive that even early detection is too late to benefit the patient (women who die despite detection by mammography). Cancers that would have receded on their own or are so slow growing that the woman would die of other causes before the cancer produced symptoms (mammography results in over diagnosis and over treatment of this class). A small number of breast cancers that are detected by screening mammography and whose treatment outcome improves as a result of earlier detection. Only 3% to 13% of breast cancers detected by screening mammography will fall into this last category. Clinical trial data suggests that 1 woman per 1,000 healthy women screened over 10 years falls into this category. A 2016 review for the United States Preventive Services Task Force found that mammography was associated with an 8% 33% decrease in breast cancer mortality in different age groups, but that this decrease was not statistically significant at the age groups of 39–49 and 70–74. The same review found that mammography significantly decreased the risk of advanced cancer among women aged 50 and older by 38%, but among those aged 39 to 49 the risk reduction was a non significant 2%. The USPSTF made their review based on data from randomized controlled trials (RCT) studying breast cancer in women between the ages of 40 49. that false positive mammograms may affect women's well being and behavior. Some women who receive false positive results may be more likely to return for routine screening or perform breast self examinations more frequently. However, some women who receive false positive results become anxious, worried, and distressed about the possibility of having breast cancer, feelings that can last for many years. False positives also mean greater expense, both for the individual and for the screening program. Since follow up screening is typically much more expensive than initial screening, more false positives (that must receive follow up) means that fewer women may be screened for a given amount of money. Thus as sensitivity increases, a screening program will cost more or be confined to screening a smaller number of women.

The central harm of mammographic breast cancer screening is overdiagnosis: the detection of abnormalities that meet the pathologic definition of cancer but will never progress to cause symptoms or death. Dr. H. Gilbert Welch, a researcher at Dartmouth College, states that "screen detected breast and prostate cancer survivors are more likely to have been over diagnosed than actually helped by the test." In 2009, Peter C. Gotzsche and Karsten Juhl Jørgensen reviewed the literature and found that 1 in 3 cases of breast cancer detected in a population offered mammographic screening is over diagnosed. In contrast, a 2012 panel convened by the national cancer director for England and Cancer Research UK concluded that 1 in 5 cases of breast cancer diagnosed among women who have undergone breast cancer screening are over diagnosed. This means an over diagnosis rate of 129 women per 10,000 invited to screening. A recent systematic review of 30 studies found that screening mammography for breast cancer among women aged 40 years and older was 12.6%.

Mammograms also have a rate of missed tumors, or "false negatives". Accurate data regarding the number of false negatives are very difficult to obtain because mastectomies cannot be performed on every woman who has had a mammogram to determine the false negative rate. Estimates of the false negative rate depend on close follow up of a large number of patients for many years. This is difficult in practice because many women do not return for regular mammography making it impossible to know if they ever developed a cancer. In his book The Politics of Cancer, Dr. Samuel S. Epstein claims that in women ages 40 to 49, one in four cancers are missed at each mammography. Researchers have found that breast tissue is denser among younger women, making it difficult to detect tumors. For this reason, false negatives are twice as likely to occur in pre menopausal mammograms (Prate). This is why the screening program in the UK does not start calling women for screening mammograms until age 50. The importance of these missed cancers is not clear, particularly if the woman is getting yearly mammograms. Research on a closely related situation has shown that small cancers that are not acted upon immediately, but are observed over periods of several years, will have good outcomes. A group of 3,184 women had mammograms that were formally classified as "probably benign". This classification is for patients who are not clearly normal but have some area of minor concern. This results not in the patient being biopsied, but rather in having early follow up mammography every six months for three years to determine whether there has been any change in status. Of these 3,184 women, 17 (0.5%) did have cancers. Most importantly, when the diagnosis was finally made, they were all still stage 0 or 1, the earliest stages. Five years after treatment, none of these 17 women had evidence of re occurrence. Thus, small early cancers, even though not acted on immediately, were still reliably curable.

Breast cancer imposes a significant economic strain on communities, with the expense of treating stages three and four in the United States in 2017 amounting to approximately $127,000. While early diagnosis and screening methods are important in reducing the death rates, the cost benefit of breast cancer screening using mammography has been unclear. A recent systematic review of three studies held in Spain, Denmark, and the United States from 2000 2019 found that digital mammography is not cost beneficial for the healthcare system when compared to other screening methods. Therefore, increasing its frequency may cause higher costs on the healthcare system. While there may be a lack of evidence, it is suggested that digital mammography be performed every two years for ages over 50.

As the USPSTF recommendations are so influential, changing mammography screenings from 50 to 40 years of age has significant implications to public health. The major concerns regarding this update is whether breast cancer mortality has truly been increasing and if there is new evidence that the benefits of mammography are increasing. According to National Vital Statistics System, mortality from breast cancer has been steadily decreasing in the United States from 2018 to 2021. There have also been no new randomized trials of screening mammography for women in their 40s since the previous USPSTF recommendation was made. In addition, the 8 most recent randomized trials for this age group revealed no significant effect. Instead, the USPSTF used statistical models to estimate what would happen if the starting age were lowered, assuming that screening mammography reduces breast cancer mortality by 25%. This found that screening 1,000 women from 40–74 years of age, instead of 50 74, would cause 1 2 fewer breast cancer deaths per 1,000 women screened over a lifetime. Approximately 75 percent of women diagnosed with breast cancer have no family history of breast cancer or other factors that put them at high risk for developing the disease (so screening only high risk women misses majority of cancers). An analysis by Hendrick and Helvie, published in the American Journal of Roentgenology, showed that if USPSTF breast cancer screening guidelines were followed, approximately 6,500 additional women each year in the U. S. would die from breast cancer. The largest (Hellquist et al) and longest running (Tabar et al) breast cancer screening studies in history re confirmed that regular mammography screening cut breast cancer deaths by roughly a third in all women ages 40 and over (including women ages 40–49). This renders the USPSTF calculations off by half. They used a 15% mortality reduction to calculate how many women needed to be invited to be screened to save a life. With the now re confirmed 29% (or up) figure, the number to be screened using the USPSTF formula is half of their estimate and well within what they considered acceptable by their formula.

Many factors affect how many people attend breast cancer screenings. For example, people from minority ethnic communities are also less likely to attend cancer screening. In the UK, women of South Asian heritage are the least likely to attend breast cancer screening. Research is still needed to identify specific barriers for the different South Asian communities. For example, a study showed that British Pakistani women faced cultural and language barriers and were not aware that breast screening takes place in a female only environment. People with mental illnesses are also less likely to attend cancer screening appointments. In Northern Ireland women with mental health problems were shown to be less likely to attend screening for breast cancer, than women without. The lower attendance numbers remained the same even when marital status and social deprivation were taken into account.

Mammography facilities in the United States and its territories (including military bases) are subject to the Mammography Quality Standards Act (MQSA). The act requires annual inspections and accreditation every three years through an FDA approved body. Facilities found deficient during the inspection or accreditation process can be barred from performing mammograms until corrective action has been verified or, in extreme cases, can be required to notify past patients that their exams were sub standard and should not be relied upon. At this time, MQSA applies only to traditional mammography and not to related scans, such as breast ultrasound, stereotactic breast biopsy, or breast MRI. As of September 10, 2024, the MQSA requires that all patients be notified of their breast density ("dense" or "not dense") in their mammogram reports.

Recently, artificial intelligence (AI) programs have been developed to utilize features from screening mammography images to predict breast cancer risk. A systematic review of 16 retrospective study designs comparing median maximum AUC found that artificial intelligence had a comparable or better accuracy (AUC = 0.72) of predicting breast cancer than clinical risk factors alone (AUC = 0.61), suggesting a transition from clinical risk factor based to AI image based risk models may lead to more accurate and personalized risk based screening approaches. Another study of 32 published papers involving 23,804 mammograms and various machine learning methods (CNN, ANN, and SVM) found promising results in the ability to assist clinicians in large scale population based breast cancer screening programs.

For patients who do not want to undergo mammography, MRI and also breast computed tomography (also called breast CT) offer a painless alternative. Whether the respective method is suitable depends on the clinical picture; it is decided by the physician.